Hubert Aroule, VP Business Operations and Finance, Septodont India, in conversation with Shahid Akhter, ENN, talks about the latest developments with applications in restorative and endodontic segments
Please tell us about Septodont products available in India. Also elaborate upon your latest and the most innovative products in India.
Septodont is a dental pharmaceutical company with the products categorised into drugs and medical devices for treatment in almost every dental specialty. The product range includes topical as well as injectable local anesthetics, needles and syringes, products for endodontics, periodontics and dental surgical procedures.
Cross contamination is the biggest threat in dental practice and Septodont has products also for disinfection and hygiene for the safety of both dentist as well as patients.
Tell us about the Septodont manufacturing plant in India?
Septodont has world class manufacturing facility at Taloja MIDC in New Mumbai. In fact, Septodont was the first MNC to start its manufacturing plant in India for dental materials way back in 2001. We became the first company in India which indigenouslyÂ manufactured its Plastalgin alginates brand â a flagship product. We are also manufacturing Dental Impression material, mouth-wash, disinfectants and other hygiene-related Products. Our facility is ISO 9001 & 13485 Certified. The facility is also certified by FDA Maharashtra for GMP (Good Manufacturing Practices) Certification.
Did Septodont participate in the FDI World Dental Congress held last month?
Yes, we were present and it was anÂ ideal time for the company to showcase its latest products in pain control, pulp vitality preservation and bone grafting. Septodont presented the Ultra Safety Plus â a single-use sterile device with protective sheath and handle and Septoject Evolution â a dental needle designed with a larger interior diameter to reduce pressureÂ at injection. We also showcased our new launch RTR (Reabsorbable Tissue Replacement) solution which is the apt brand name for a very unique formulation. It is a very simple and easy to use solution for even complex bone augmentation therapies. RTR releases Calcium and phosphate ions to promote strong new bone formation and regenerates new bone in 3 to 6 months.
“Septodont was the first MNC to start its manufacturing plant in India for dental materials way back in 2001”
At Septodontâs booth, visitors were introduced to Septodontâs latest developments with applications in restorative and endodontic segments. The company thus patented in these segments two breakthrough technology platforms called Nano-Dimer Conversion Technology â NâDurance Range and âActivate Biosilicate Technology.â Bio-active dentine substitute Biodentine received a tremendous response all over the world due to its versatile usage in restorative procedures. It is the only one material for Dentin bulk replacement and has very unique bio-compatible properties. Biodentine keeps the pulp vital and virtually eliminates post-operativeÂ pain. Biodentine saves patients from undergoing unnecessary endo treatment and saves at least 45 minutes for Dentist. All in all, Biodentine is pulp friendly, time saving, cost effective and safe.
Unique curved syringe of RTR Bone graft material has now become the preferred choice for Implant Specialists, Oral Surgeons and Periodontists around the world due to its ease of placement. RTR is also available as RTR granules and RTR cone to offer different choices to dentists depending on their needs.
What in your opinion makes your product particularly suitable for the Indian market?
Consistency in quality and range of products for all dental specialties with a very competitive price, make our products suitable for Indian market. Septodontâs efforts to manufacture some of these products in local plants to make them cost effective — without compromising its high quality standards — has been appreciated by the dental world in India.
Compared to other markets you operate in, what particular challenges does the Indian market pose?
India is a very price-sensitive market and to offer the same quality as in other strict quality conscious markets in the world is a big challenge. However, it is a conscious decision taken by our parent company to operate in India with âNo profit â no lossâ equation or minimum profit margin.
How do you visualise the opportunity for Septodont to cater to the Indian market?
Septodont has been always present in Indian market and is now having a strong foothold due to its commitment to dentistry and the trust shown byÂ dentists in India. Some of the products are so unique in their features that they canât be replaced with any competitive products.
“Some of the products are so unique in their features that they canât be replaced with any competitive products”
You have to face increased competition from local providers offering similar products at lower costs. How do you see the oral healthcare infrastructure and the emerging market in India?
When it comes to quality, there is no competition for Septodont at least from locally-manufactured products. However, our goal is not to cater only to niche customer segment but also to make the same quality more affordable even for dentists in small towns and interiors.
Technology comes at a price. How do you intend to introduce the latest technologies at a competitive price?
Of course, technology comes with price but our motto is service to the mankind. Septodont has been doing a lot of work in research and development of new technologies to make dental treatment s i m p l e r, time saving and cost effective. As we say,Â time is money, this will offer more ROI to dentists and lesser treatment cost to patients due to reduced number of visits to clinic. At the same time we are trying to provide dental treatment in the most remote areas in the world by providing free products in the camps run by social organisations. Similarly, our management always decides the prices to different countries depending on the socio-economic condition, dental awareness and affordability in general. Therefore, prices of our products in India are much lesser compared to developed countries in Europe and America.
What general prospects do you see for your company in India for the years to come? What further plans do you have for the region?
Our strategy is to manufacture more and more products in India and sell them in India as well as neighbouring countries. We also intend to penetrate even the smallest towns across the country. If we increase our market share to the expected level, we may invest in one more plant in the country.